Dated: January 6, 2022

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

IN RE: VALSARTAN, LOSARTAN, AND IRBESARTAN PRODUCTS LIABILITY LITIGATION

MDL No. 2875

THIS DOCUMENT RELATES TO ALL

HON. ROBERT B. KUGLER CIVIL NO. 19-2875 (RBK)

CASES

CERTIFICATION OF C. BRETT VAUGHN IN SUPPORT OF PLAINTIFFS' REPLY BRIEF IN SUPPORT OF DAUBERT MOTION TO EXCLUDE TESTIMONY OF JON P. FRYZEK, MPH, PH.D.

C. BRETT VAUGHN, hereby certifies as follows:

- 1. I am an attorney at law within the State of Kansas with the Hollis Law Firm, and serve on the Plaintiff's Executive Committee. I am fully familiar with the facts and circumstances of these actions. I make this Certification in support of Plaintiffs' reply brief in support of *Daubert* motion to exclude the testimony of Jon P. Fryzek, MPH, Ph.D.
- 2. Attached hereto as **Exhibit S** is a true and accurate copy of ZHP02563327 Deviation Investigation Report, Investigation Regarding Unknown Impurity (Genotoxic Impurity) of Valsartan API (TEA process), Annex 1c.2, DCE-18003 V2 for valsartan, 2018.

HOLLIS LAW FIRM Attorneys for Plaintiffs

By: /s/ C. Brett Vaughn

C. Brett Vaughn RN, BSN, JD